Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Identification of potent inhibitors of SARS-CoV-2 infection by combined pharmacological evaluation and cellular network prioritization.
Patten JJ, Keiser PT, Morselli-Gysi D, Menichetti G, Mori H, Donahue CJ, Gan X, Valle ID, Geoghegan-Barek K, Anantpadma M, Boytz R, Berrigan JL, Stubbs SH, Ayazika T, O'Leary C, Jalloh S, Wagner F, Ayehunie S, Elledge SJ, Anderson D, Loscalzo J, Zitnik M, Gummuluru S, Namchuk MN, Barabási AL, Davey RA. Patten JJ, et al. Among authors: berrigan jl. iScience. 2022 Sep 16;25(9):104925. doi: 10.1016/j.isci.2022.104925. Epub 2022 Aug 13. iScience. 2022. PMID: 35992305 Free PMC article.
Novel ELISA Protocol Links Pre-Existing SARS-CoV-2 Reactive Antibodies With Endemic Coronavirus Immunity and Age and Reveals Improved Serologic Identification of Acute COVID-19 via Multi-Parameter Detection.
Yuen RR, Steiner D, Pihl RMF, Chavez E, Olson A, Smith EL, Baird LA, Korkmaz F, Urick P, Sagar M, Berrigan JL, Gummuluru S, Corley RB, Quillen K, Belkina AC, Mostoslavsky G, Rifkin IR, Kataria Y, Cappione AJ 3rd, Gao W, Lin NH, Bhadelia N, Snyder-Cappione JE. Yuen RR, et al. Among authors: berrigan jl. Front Immunol. 2021 Apr 9;12:614676. doi: 10.3389/fimmu.2021.614676. eCollection 2021. Front Immunol. 2021. PMID: 33897682 Free PMC article.
CD209L/L-SIGN and CD209/DC-SIGN Act as Receptors for SARS-CoV-2.
Amraei R, Yin W, Napoleon MA, Suder EL, Berrigan J, Zhao Q, Olejnik J, Chandler KB, Xia C, Feldman J, Hauser BM, Caradonna TM, Schmidt AG, Gummuluru S, Mühlberger E, Chitalia V, Costello CE, Rahimi N. Amraei R, et al. ACS Cent Sci. 2021 Jul 28;7(7):1156-1165. doi: 10.1021/acscentsci.0c01537. Epub 2021 Jun 30. ACS Cent Sci. 2021. PMID: 34341769 Free PMC article.
CD209L/L-SIGN and CD209/DC-SIGN act as receptors for SARS-CoV-2.
Amraei R, Yin W, Napoleon MA, Suder EL, Berrigan J, Zhao Q, Olejnik J, Chandler KB, Xia C, Feldman J, Hauser BM, Caradonna TM, Schmidt AG, Gummuluru S, Muhlberger E, Chitalia V, Costello CE, Rahimi N. Amraei R, et al. bioRxiv [Preprint]. 2021 Jun 14:2020.06.22.165803. doi: 10.1101/2020.06.22.165803. bioRxiv. 2021. Update in: ACS Cent Sci. 2021 Jul 28;7(7):1156-1165. doi: 10.1021/acscentsci.0c01537. PMID: 32607506 Free PMC article. Updated. Preprint.
Identification of druggable host targets needed for SARS-CoV-2 infection by combined pharmacological evaluation and cellular network directed prioritization both in vitro and in vivo.
Patten JJ, Keiser PT, Gysi D, Menichetti G, Mori H, Donahue CJ, Gan X, do Valle I, Geoghegan-Barek K, Anantpadma M, Boytz R, Berrigan JL, Hulsey-Stubbs S, Ayazika T, O'Leary C, Jalloh S, Wagner F, Ayehunie S, Elledge SJ, Anderson D, Loscalzo J, Zitnik M, Gummuluru S, Namchuk MN, Barabási AL, Davey RA. Patten JJ, et al. Among authors: berrigan jl. bioRxiv [Preprint]. 2022 Feb 1:2021.04.20.440626. doi: 10.1101/2021.04.20.440626. bioRxiv. 2022. Update in: iScience. 2022 Sep 16;25(9):104925. doi: 10.1016/j.isci.2022.104925. PMID: 33907750 Free PMC article. Updated. Preprint.